US6143746A
(en)
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
GB9511220D0
(en)
*
|
1995-06-02 |
1995-07-26 |
Glaxo Group Ltd |
Solid dispersions
|
US5874440A
(en)
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
US6046216A
(en)
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
US6060477A
(en)
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
GB9514464D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
SK154498A3
(en)
*
|
1996-05-10 |
2000-01-18 |
Icos Corp |
Carboline derivatives, process for the preparation thereof, pharmaceutical compositions containing same and use of mentioned derivatives as drugs
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
US6331543B1
(en)
*
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
US6071934A
(en)
|
1997-03-25 |
2000-06-06 |
Cell Pathways, Inc. |
Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
|
EP0998274B1
(fr)
|
1997-06-23 |
2006-01-18 |
Cellegy Pharmaceuticals, Inc |
Traitement par administration de microdoses
|
US6403597B1
(en)
*
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
IL132406A0
(en)
*
|
1998-10-21 |
2001-03-19 |
Pfizer Prod Inc |
Treatment of bph with cgmp elevators
|
US6133271A
(en)
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
US6211220B1
(en)
|
1998-11-23 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
US6420410B1
(en)
|
1998-11-24 |
2002-07-16 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6358992B1
(en)
|
1998-11-25 |
2002-03-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with indole derivatives
|
DE60007289T2
(de)
|
1999-03-24 |
2004-10-21 |
Harbor Branch Oceanographic |
Verwendung von manzaminen als entzündungshemmende mittel
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
MXPA00003997A
(es)
*
|
1999-04-30 |
2002-03-08 |
Lilly Icos Llc |
Articulos de fabricacion.
|
US6943166B1
(en)
*
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
US6821975B1
(en)
|
1999-08-03 |
2004-11-23 |
Lilly Icos Llc |
Beta-carboline drug products
|
UA72922C2
(uk)
|
1999-08-03 |
2005-05-16 |
Ліллі Айкос Ллк |
ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ
|
BR0014695A
(pt)
|
1999-10-11 |
2002-06-18 |
Pfizer |
5-(2-substituìdo-5-heterociclilsulfonilpirid-3-il)-dihi dropirazolo[4,3-d]pirimidin-7-onas como inibidoras de fosfodiesterase
|
TWI224966B
(en)
*
|
1999-11-02 |
2004-12-11 |
Pfizer |
Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
|
US6562830B1
(en)
|
1999-11-09 |
2003-05-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
|
US6376489B1
(en)
*
|
1999-12-23 |
2002-04-23 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
EP1278522B1
(fr)
|
2000-04-19 |
2006-10-25 |
Lilly Icos LLC |
Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson
|
UA74826C2
(en)
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
JP2004501124A
(ja)
*
|
2000-06-07 |
2004-01-15 |
リリー アイコス リミテッド ライアビリティ カンパニー |
化合物
|
WO2002000658A1
(fr)
*
|
2000-06-23 |
2002-01-03 |
Lilly Icos Llc |
Inhibiteurs de phosphodiesterase specifique de gmp cyclique
|
JP4169149B2
(ja)
*
|
2000-06-23 |
2008-10-22 |
リリー アイコス リミテッド ライアビリティ カンパニー |
化学的化合物
|
US6903099B2
(en)
|
2000-06-26 |
2005-06-07 |
Lilly Icos Llc |
Condensed pyrazindione derivatives
|
AU2001278480A1
(en)
*
|
2000-07-24 |
2002-02-05 |
Bayer Crop Science Ag |
Biphenyl carboxamides
|
US7034027B2
(en)
*
|
2000-08-02 |
2006-04-25 |
Lilly Icos Llc |
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
US20040092494A9
(en)
*
|
2000-08-30 |
2004-05-13 |
Dudley Robert E. |
Method of increasing testosterone and related steroid concentrations in women
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
ES2244659T3
(es)
*
|
2000-10-02 |
2005-12-16 |
Lilly Icos Llc |
Derivados de hexahidropirazino (1'2':1,6)-pirido(3,4-b)indol-1,4-diona para el tratamiento de trastornos cardiovasculares y disfuncion erectil.
|
AU2002213419A1
(en)
|
2000-10-02 |
2002-04-15 |
Lilly Icos Llc |
Condensed pyridoindole derivatives
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
US6828473B2
(en)
|
2000-11-01 |
2004-12-07 |
Pfizer Inc. |
Modulation of PDE11A activity
|
EP1211313A3
(fr)
*
|
2000-11-01 |
2003-04-23 |
Pfizer Limited |
Modulation de l'activité PDE11A activity
|
AU2002211493A1
(en)
*
|
2000-11-06 |
2002-05-15 |
Lilly Icos Llc |
Indole derivatives as pde5-inhibitors
|
DE60216745T2
(de)
*
|
2001-04-25 |
2007-05-16 |
Lilly Icos Llc, Wilmington |
Chemische Verbindungen
|
DE60219788T2
(de)
*
|
2001-06-05 |
2008-01-17 |
Lilly Icos Llc, Wilmington |
Tetrazyklische verbindungen als pde5-inhibitoren
|
US7098209B2
(en)
|
2001-06-05 |
2006-08-29 |
Lilly Icos Llc |
Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives
|
EP1401835A1
(fr)
|
2001-06-05 |
2004-03-31 |
Lilly Icos LLC |
Derives de carboline utilises comme inhibiteurs de pde-5
|
ES2269679T3
(es)
|
2001-06-21 |
2007-04-01 |
Lilly Icos Llc |
Derivados de carbolina como inhibidores de pdev.
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
WO2003042216A1
(fr)
*
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Inhibiteurs de la phosphodiesterase v de derives polycycliques de guanine
|
US6686349B2
(en)
*
|
2001-11-14 |
2004-02-03 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
JP2005529927A
(ja)
*
|
2002-05-23 |
2005-10-06 |
ファイザー インコーポレイテッド |
新規な組み合わせ
|
EP1719772A1
(fr)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Procédé de préparation d'inhibiteurs de la phosphodiesterase v de la xanthine et leur précurseurs
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
JP2005536567A
(ja)
*
|
2002-07-31 |
2005-12-02 |
リリー アイコス リミテッド ライアビリティ カンパニー |
ピクテ−スペングラー反応の変法およびその産物
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
ES2341240T3
(es)
|
2002-12-13 |
2010-06-17 |
Warner-Lambert Company Llc |
Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
|
KR20050115331A
(ko)
|
2003-04-01 |
2005-12-07 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
불임증 포스포디에스터라제의 억제제
|
JP4015176B2
(ja)
|
2003-04-29 |
2007-11-28 |
ファイザー・インク |
高血圧症の治療に有用な5,7−ジアミノピラゾロ4,3−ジピリミジン類
|
US20060094723A1
(en)
*
|
2003-05-22 |
2006-05-04 |
Torsten Dunkern |
Composition comprising a pde4 inhibitor and a pde5 inhibitor
|
EP3342420A1
(fr)
*
|
2003-06-13 |
2018-07-04 |
Ironwood Pharmaceuticals, Inc. |
Procédé et compositions de traitement des troubles gastro-intestinaux
|
JP4671123B2
(ja)
|
2003-06-23 |
2011-04-13 |
小野薬品工業株式会社 |
新規三環性複素環化合物
|
US7291640B2
(en)
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
JP2007514665A
(ja)
*
|
2003-12-12 |
2007-06-07 |
ミオゲン インコーポレイティッド |
エノキシモン製剤ならびに心肥大および心不全の治療へのそれらの使用方法
|
WO2005068464A2
(fr)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Procede de preparation de tadalafil et ses intermediaires
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
US20060025463A1
(en)
*
|
2004-03-22 |
2006-02-02 |
Michael Bristow |
Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
|
WO2005092333A1
(fr)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxyde et son utilisation dans le traitement de maladies induites par pde-iii
|
DK1742950T3
(da)
|
2004-04-07 |
2009-03-16 |
Pfizer Ltd |
Pyrazolo-[4,3-D]-pyrimidiner
|
WO2005116030A1
(fr)
*
|
2004-05-31 |
2005-12-08 |
Matrix Laboratories Ltd |
Procede d'elaboration de tadalafil
|
EP1776108A1
(fr)
*
|
2004-06-23 |
2007-04-25 |
Myogen, Inc. |
Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
|
CN101106997A
(zh)
|
2004-08-17 |
2008-01-16 |
约翰·霍普金斯大学 |
Pde5抑制剂组合物及治疗心脏病征候的方法
|
EP1804582A4
(fr)
*
|
2004-10-28 |
2009-12-09 |
Reddys Lab Ltd Dr |
Formes polymorphiques du tadalafil
|
WO2006050458A2
(fr)
*
|
2004-11-02 |
2006-05-11 |
Teva Pharmaceutical Industries, Ltd. |
Formes cristallines de tadalafil et leurs procedes de preparation
|
AR051780A1
(es)
*
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
EP1829874B1
(fr)
|
2004-12-22 |
2014-02-12 |
Ono Pharmaceutical Co., Ltd. |
Compose tricyclique et son utilisation
|
MX2007010431A
(es)
*
|
2005-02-25 |
2007-10-11 |
Teva Pharma |
Proceso para purificar tadalafil.
|
US20060293331A1
(en)
*
|
2005-02-25 |
2006-12-28 |
Ben-Zion Dolitzky |
Process of synthesizing tadalafil
|
US7417044B2
(en)
*
|
2005-02-25 |
2008-08-26 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil having a large particle size and a process for preparation thereof
|
US20070088012A1
(en)
*
|
2005-04-08 |
2007-04-19 |
Woun Seo |
Method of treating or preventing type-2 diabetes
|
JP2008538554A
(ja)
*
|
2005-04-12 |
2008-10-30 |
テバ ファーマシューティカル インダストリーズ リミティド |
タダラフィルの中間体の調製
|
PT2366393E
(pt)
|
2005-04-19 |
2013-10-04 |
Takeda Gmbh |
Roflumilaste para o tratamento da hipertensão pulmonar
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
BRPI0609225A2
(pt)
|
2005-05-12 |
2010-03-09 |
Pfizer |
formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
WO2007016361A2
(fr)
*
|
2005-07-29 |
2007-02-08 |
Concert Pharmaceuticals Inc. |
Nouveaux composes pharmaceutiques
|
US7863274B2
(en)
*
|
2005-07-29 |
2011-01-04 |
Concert Pharmaceuticals Inc. |
Deuterium enriched analogues of tadalafil as PDE5 inhibitors
|
ES2646326T3
(es)
|
2005-08-03 |
2017-12-13 |
Sprout Pharmaceuticals, Inc. |
Uso de flibanserina en el tratamiento de la obesidad
|
EP2275095A3
(fr)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenese par modulation des recepteurs muscariniques
|
EP2258358A3
(fr)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenèse avec un inhibiteur de l'acetylcholinestérase
|
JP2009507925A
(ja)
*
|
2005-09-13 |
2009-02-26 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子タダラフィル製剤
|
RS52671B
(en)
|
2005-10-12 |
2013-06-28 |
Unimed Pharmaceuticals Llc |
IMPROVED TESTOSTERON GEL AND USE PROCEDURE
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス,インコーポレイティド |
Pde阻害による神経新生の調節
|
CA2626134C
(fr)
|
2005-10-29 |
2013-12-24 |
Boehringer Ingelheim International Gmbh |
Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
|
CA2625210A1
(fr)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
|
WO2007100387A2
(fr)
*
|
2005-11-03 |
2007-09-07 |
Dr. Reddy's Laboratories Ltd. |
Procédé de préparation de tadalafil
|
AU2006311577B2
(en)
|
2005-11-09 |
2013-02-07 |
Zalicus Inc. |
Methods, compositions, and kits for the treatment of medical conditions
|
US7202229B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
US7201929B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
US20070244143A1
(en)
*
|
2006-03-08 |
2007-10-18 |
Braincells, Inc |
Modulation of neurogenesis by nootropic agents
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007110734A1
(fr)
*
|
2006-03-24 |
2007-10-04 |
Glenmark Pharmaceuticals Limited |
Procede de preparation de tadalafil
|
WO2007124045A2
(fr)
*
|
2006-04-20 |
2007-11-01 |
Ampla Pharmaceuticals, Inc. |
Potentialisation d'activité de récepteur mc4
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
JP2009536667A
(ja)
*
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
5ht受容体介在性の神経新生
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
US20090291958A1
(en)
*
|
2006-06-08 |
2009-11-26 |
Auspex Pharmaceuticals, Inc. |
Substituted PDE5 inhibitors
|
DE602007004615D1
(de)
|
2006-06-30 |
2010-03-18 |
Boehringer Ingelheim Pharma |
Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
|
WO2008005039A1
(fr)
*
|
2006-07-07 |
2008-01-10 |
Teva Pharmaceutical Industries Ltd. |
Compositions solides comprenant du tadalafil et au moins un véhicule
|
JP2009544617A
(ja)
|
2006-07-21 |
2009-12-17 |
ノバルティス アクチエンゲゼルシャフト |
ベンゾイミダゾリルピリジルエーテルの製剤
|
AR062320A1
(es)
|
2006-08-14 |
2008-10-29 |
Boehringer Ingelheim Int |
Formulaciones de flibanserina y metodo para fabricarlas
|
EA200900270A1
(ru)
|
2006-08-25 |
2009-08-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Системы регулируемого высвобождения и способ их приготовления
|
AR062501A1
(es)
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
KR20090064418A
(ko)
*
|
2006-09-08 |
2009-06-18 |
브레인셀즈 인코퍼레이션 |
4-아실아미노피리딘 유도체 포함 조합물
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
WO2008036678A2
(fr)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
Modulation induite par ppar de la neurogenèse
|
US20080139593A1
(en)
|
2006-12-12 |
2008-06-12 |
Gerber Michael J |
Method for treating a pulmonary hypertension condition
|
WO2008095136A2
(fr)
|
2007-01-31 |
2008-08-07 |
Henkin Robert I |
Procédés de détection de substances biologiques
|
WO2008100933A2
(fr)
|
2007-02-12 |
2008-08-21 |
Dmi Biosciences, Inc. |
Réduction des effets secondaires du tramadol
|
CA2677690C
(fr)
*
|
2007-02-12 |
2012-05-15 |
James V. Winkler |
Traitement destine a une ejaculation precoce et aux troubles de l'erection comorbides
|
WO2008103470A2
(fr)
*
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Composés létaux dépendants du signal de ras oncogénique
|
KR20100012867A
(ko)
*
|
2007-04-25 |
2010-02-08 |
테바 파마슈티컬 인더스트리즈 리미티드 |
타다라필을 포함하는 고체 제형
|
FR2916200A1
(fr)
*
|
2007-05-18 |
2008-11-21 |
Fourtillan Snc |
Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
|
DE102007028869A1
(de)
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
DK2170880T3
(da)
|
2007-06-29 |
2012-09-10 |
Ranbaxy Lab Ltd |
Fremgangsmåde til fremstillingen af mellemprodukter af tetracycliske forbindelser
|
EP2033962A1
(fr)
*
|
2007-08-22 |
2009-03-11 |
4Sc Ag |
Dérivés tétracycliques d'indolopyridines comme inhibiteurs de EG5
|
CL2008002693A1
(es)
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
US20090181975A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
ITMI20080285A1
(it)
*
|
2008-02-22 |
2009-08-23 |
Endura Spa |
Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
|
EP2107059A1
(fr)
*
|
2008-03-31 |
2009-10-07 |
LEK Pharmaceuticals D.D. |
Conversion de tryptophane en dérivés de ß-carboline
|
PL385356A1
(pl)
|
2008-06-03 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania tadalafilu
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
EP2181997A1
(fr)
|
2008-10-30 |
2010-05-05 |
Chemo Ibérica, S.A. |
Procédé de préparation de tadalafil
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
EP2379076B1
(fr)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
|
WO2010099217A1
(fr)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
|
EP2400848A4
(fr)
|
2009-02-26 |
2012-07-25 |
Thar Pharmaceuticals Inc |
Cristallisation de composés pharmaceutiques
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
EP2556820A4
(fr)
|
2010-04-05 |
2015-01-21 |
Sk Chemicals Co Ltd |
Composition contenant un inhibiteur de pde5 pour l'atténuation des rides de la peau
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
KR20150002876A
(ko)
|
2010-10-15 |
2015-01-07 |
길리애드 사이언시즈, 인코포레이티드 |
폐 고혈압 치료의 조성물 및 방법
|
WO2012107090A1
(fr)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Composition de granulés comportant du tadalafil et un délitant
|
WO2012107092A1
(fr)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Composition pharmaceutique comportant du tadalafil et une cyclodextrine
|
US8829023B2
(en)
|
2011-02-10 |
2014-09-09 |
Interquim, S.A. |
Process for obtaining compounds derived from tetrahydro-β-carboline
|
RU2013141446A
(ru)
|
2011-02-10 |
2015-03-20 |
Синтон Бв |
Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
|
US20120123124A1
(en)
*
|
2011-04-22 |
2012-05-17 |
Drug Process Licensing Associates, LLC |
Manufacturing process for Tadalafil from racemic or L-tryptophan
|
CN102180876B
(zh)
*
|
2011-05-28 |
2016-05-18 |
浙江华海药业股份有限公司 |
一种他达那非晶型i的制备方法
|
EP2535049A1
(fr)
|
2011-06-17 |
2012-12-19 |
Proyecto de Biomedicina Cima, S.L. |
Tadalafil pour le traitement de la démence
|
CN102367253B
(zh)
*
|
2011-09-20 |
2016-04-06 |
浙江华海药业股份有限公司 |
一种制备他达拉非晶型a的方法
|
WO2013067309A1
(fr)
|
2011-11-04 |
2013-05-10 |
Xion Pharmaceutical Corporation |
Procédés et compositions pour l'administration orale de composés agonistes d'un récepteur de la mélanocortine
|
WO2013106547A1
(fr)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
|
WO2013109738A1
(fr)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
|
WO2013109223A1
(fr)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Formulations de particules de tadalafil sous forme effervescente
|
WO2013109230A1
(fr)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Compositions pharmaceutiques contenant du tadalafil
|
WO2013109225A1
(fr)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Formulations pharmaceutiques en comprimés comprenant du ceftibutène
|
JP5941558B2
(ja)
|
2012-02-28 |
2016-06-29 |
株式会社ソウル製薬Seoul Pharma. Co., Ltd. |
シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
|
WO2014055801A1
(fr)
|
2012-10-05 |
2014-04-10 |
Henkin Robert I |
Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
|
KR102146673B1
(ko)
|
2012-12-04 |
2020-08-21 |
주식회사 아리바이오 |
포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
ES2882258T3
(es)
|
2012-12-21 |
2021-12-01 |
Mayo Found Medical Education & Res |
Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
|
MX2015010725A
(es)
|
2013-02-21 |
2016-05-31 |
Adverio Pharma Gmbh |
Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
|
CN103232451A
(zh)
*
|
2013-05-14 |
2013-08-07 |
张家港威胜生物医药有限公司 |
一种他达那非的简易制备工艺
|
EP3022205B1
(fr)
|
2013-07-17 |
2020-02-05 |
The Trustees of Columbia University in the City of New York |
Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
|
EP3082428A4
(fr)
|
2013-12-09 |
2017-08-02 |
Respira Therapeutics, Inc. |
Formulations en poudre d'inhibiteur pde5 et procédés y associés
|
WO2015126944A1
(fr)
|
2014-02-18 |
2015-08-27 |
Henkin Robert I |
Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
|
AR099416A1
(es)
|
2014-02-28 |
2016-07-20 |
Lilly Co Eli |
Terapia combinada para la hipertensión resistente
|
MX2016014384A
(es)
|
2014-06-23 |
2017-01-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
|
ES2784251T3
(es)
|
2014-06-30 |
2020-09-23 |
Montero Gida Sanayi Ve Ticaret As |
Formulaciones de disgregación por vía oral de tadalafilo
|
EP2962684A1
(fr)
|
2014-06-30 |
2016-01-06 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Formulations de tadalafil se désintégrant par voie orale
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
EP3466951B1
(fr)
|
2014-07-23 |
2022-01-19 |
KRKA, d.d., Novo mesto |
Procédé de préparation d'inhibiteur de cgmp-phosphodiestérase et formulation pharmaceutique orale comprenant des co-précipités de tadalafil
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
KR102457316B1
(ko)
*
|
2015-06-26 |
2022-10-20 |
총킹 디캉 에릴 파마 씨오. 엘티디. |
새로운 5형포스포디에스테라아제 억제제 및 그 용도
|
CN105541840B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
关键中间体及其合成方法和在制备他达拉非方面的应用
|
CN105541835B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
|
US10912778B2
(en)
|
2016-12-14 |
2021-02-09 |
Respira Therapeutics, Inc. |
Methods for treatment of pulmonary hypertension
|
CN106977516B
(zh)
*
|
2017-03-02 |
2019-06-18 |
山东裕欣药业有限公司 |
一种他达拉非的制备方法
|
RU2692764C1
(ru)
|
2019-04-26 |
2019-06-27 |
Общество с ограниченной ответственностью "Балтфарма" |
Способ получения тадалафила
|
CN111995658B
(zh)
*
|
2019-05-27 |
2022-08-02 |
首都医科大学 |
Ldv修饰的五环哌嗪二酮及其制备和应用
|
WO2021007636A1
(fr)
|
2019-07-15 |
2021-01-21 |
Biolab Sanus Farmaceutica Ltda |
Stéréoisomères du composé 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1 h-indol-3-il)-6,7-dihydro-3 h-oxazol[3,4-a]pyrazine-5,8-dione et leur utilisation comme agent antitumoral et inhibiteur de l'enzyme phosphodiestérase
|
CN110606847A
(zh)
*
|
2019-07-30 |
2019-12-24 |
中国医药集团总公司四川抗菌素工业研究所 |
一种他达拉非顺式中间体的制备方法及其应用
|
WO2021245192A1
(fr)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Nouveaux activateurs de la guanylate cyclase soluble à double mode d'action et inhibiteurs de phosphodiestérase et leurs utilisations
|